Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke

Stroke

Volumn 44, Issue 5, 2013, Pages 1354-1359

  Messé, Steven R ^a   Pervez, Muhammad A ^b   Smith, Eric E ^c   Siddique, Khawaja A ^b   Hellkamp, Anne S ^d   Saver, Jeffrey L ^e   Bhatt, Deepak L ^f   Fonarow, Gregg C ^e   Peterson, Eric D ^d   Schwamm, Lee H ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

hemorrhage; lipid lowering medication; lipids; stroke; tissue plasminogen activator

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DATABASES, FACTUAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84876879103     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.671966     Document Type: Article

References (30)

1. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703
2. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
3. Strbian D, Sairanen T, Meretoja A, Pitkäniemi J, Putaala J, Salonen O, et al; Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011;77:341-348.
4. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105:1679-1685.
5. Lou M, Safdar A, Mehdiratta M, Kumar S, Schlaug G, Caplan L, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71:1417-1423.
6. Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plas-minogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2008;17:331-333.
7. Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71:634-641.
8. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, et al; SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracere-bral hemorrhage risk score. Stroke. 2012;43:1524-1531.
9. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904-910.
10. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke. 1989;20:1460-1465.
11. Leppälä JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke. 1999;30:2535-2540.
12. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68:737-742.
13. Kim BJ, Lee SH, Ryu WS, Kang BS, Kim CK, Yoon BW. Low level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism. Stroke. 2009;40:1627-1632.
14. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, Luijckx GJ, De Keyser J. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol. 2008;255:875-880.
15. Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arte-rial thrombolysis for acute ischemic stroke. Stroke. 2009;40:1729-1737.
16. Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24 pt 2):2364-2370.
17. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124:2233-2242.
18. Martinez-Ramirez S, Delgado-Mederos R, Marín R, Suárez-Calvet M, Sáinz M P, Alejaldre A, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. J Neurol. 2012;259:111-118.
19. Smaha LA; American Heart Association. The American Heart Association Get With The Guidelines program. Am Heart J. 2004;148(5 suppl):S46-S48.
20. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda M V, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750-758.
21. Xian Y, Fonarow GC, Reeves MJ, Webb LE, Blevins J, Demyanenko VS, et al. Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. Am Heart J. 2012;163:392-398, 398.e1.
22. Wieberdink RG, Poels MM, Vernooij MW, Koudstaal PJ, Hofman A, van der Lugt A, et al. Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2011;31:2982-2989.
23. Nardi K, Engelter S, Strbian D, Sarikaya H, Arnold M, Casoni F, et al; Lipid Profile in Thrombolysis Study Group. Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia. Neurology. 2012;79:1101-1108.
24. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 1998;140:271-280.
25. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2:e123.
26. Gaddam V, Li DY, Mehta JL. Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther. 2002;7:247-253.
27. Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. Cerebrovasc Dis. 2010;29:263-267.
28. Restrepo L, Bang OY, Ovbiagele B, Ali L, Kim D, Liebeskind DS, et al. Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fbrinolysis and percutaneous mechanical embolectomy. Cerebrovasc Dis. 2009;28:384-390.
29. Alvarez-Sabín J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribó M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke. 2007;38:1076-1078.
30. Engelter ST, Soinne L, Ringleb P, Sarikaya H, Bordet R, Berrouschot J, et al. IV thrombolysis and statins. Neurology. 2011;77:888-895.